Sudden cardiac death in cardiac sarcoidosis – a subgroup analysis of the SCD-PROTECT study

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott; AstraZenca; Boehringer Ingelheim; Boston Scientific Corporation; Bristol-Myers Squibb; CVRx; Daiichi-Sankyo/Elil Lilly and Company; Medtronic; Pfizer; Zoll</li></ul>